612,412 Shares in Caribou Biosciences, Inc. (NASDAQ:CRBU) Bought by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 612,412 shares of the company's stock, valued at approximately $559,000. Cambridge Investment Research Advisors Inc. owned 0.66% of Caribou Biosciences at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of CRBU. JPMorgan Chase & Co. lifted its stake in Caribou Biosciences by 475.9% during the 4th quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock valued at $3,969,000 after acquiring an additional 2,062,563 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in Caribou Biosciences during the 4th quarter valued at approximately $1,921,000. Schonfeld Strategic Advisors LLC lifted its stake in Caribou Biosciences by 28.4% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company's stock valued at $3,360,000 after acquiring an additional 467,738 shares during the period. Two Sigma Advisers LP lifted its stake in Caribou Biosciences by 39.5% during the 4th quarter. Two Sigma Advisers LP now owns 1,470,700 shares of the company's stock valued at $2,338,000 after acquiring an additional 416,600 shares during the period. Finally, Ameriprise Financial Inc. acquired a new stake in Caribou Biosciences during the 4th quarter valued at approximately $649,000. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on CRBU shares. HC Wainwright restated a "buy" rating and set a $3.00 price objective (down from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th. Wall Street Zen upgraded shares of Caribou Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday, July 5th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $8.50.

Caribou Biosciences Stock Performance

Shares of CRBU traded down $0.11 during trading hours on Friday, hitting $1.63. The stock had a trading volume of 1,157,146 shares, compared to its average volume of 1,321,699. The firm has a 50-day moving average price of $1.16 and a 200 day moving average price of $1.18. Caribou Biosciences, Inc. has a fifty-two week low of $0.66 and a fifty-two week high of $3.00. The firm has a market capitalization of $151.59 million, a price-to-earnings ratio of -1.01 and a beta of 2.48.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.43). The firm had revenue of $2.35 million during the quarter, compared to analysts' expectations of $1.48 million. Caribou Biosciences had a negative net margin of 1,490.84% and a negative return on equity of 55.70%. As a group, analysts predict that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.